Paul Aisen, MD, Director of the ADCS, expands on the significance of the ADCS DAPC independent analysis of the semagacestat trial which was published last week in the New England Journal of Medicine.

A team of scientists, including Paul Aisen, MD, professor of neuroscience and director of the Alzheimer’s Disease Cooperative Study, issued a sort of post-mortem on semagacestat, a small-molecule gamma-secretase inhibitor that drug developer Eli Lilly hoped would prove to be an effective treatment for Alzheimer’s disease (AD).

Additional data from the Phase III Gammaglobulin Alzheimer’s Partnership (GAP) study, including select analyses of subgroups, biomarker and imaging data, was presented at the Alzheimer’s Association International Conference (AAIC) in Boston, Massachusetts

On cognitive measures, an analysis of ApoE4 carrier patients who were treated with the 400mg/kg biweekly dose (n=87) of immunoglobulin (IG), found a statistically significant difference (p=0.012) in change from baseline in the 3MS score at 18 months versus placebo.